Skip to main content
logo
Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
0.2005
-0.0100 (-4.75%)
At close: Apr 2, 2026, 4:00 PM EDT
0.2000
-0.0005 (-0.25%)
After-hours: Apr 2, 2026, 7:16 PM EDT

Ernexa Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-0.580.07--
Revenue Growth (YoY)
-755.88%---
Cost of Revenue
-0.10.24--
Gross Profit
-0.49-0.17--
Selling, General & Admin
5.1613.1314.5916.8414.72
Research & Development
4.164.66.3816.3893.24
Other Operating Expenses
-1.58--5.77
Total Operating Expenses
9.3219.3120.9733.22113.73
Operating Income
-9.32-15.67-21.14-33.22-113.73
Interest Income
0.080.25---
Interest Expense
0.036.75---
Other Non-Operating Income (Expense)
-4.87-22.33---9.65
Total Non-Operating Income (Expense)
-4.76-15.33---9.65
Pretax Income
-14.13-44.51-21.67-24.53-122.48
Provision for Income Taxes
0.05-0.030-0.05-0.06
Net Income
-14.1-44.56-21.68-24.6-122.56
Net Income Attributable to Preferred Dividends
-0.02-0.02-0.02-0.02-0.02
Net Income to Common
-14.1-44.56-21.68-24.6-122.56
Shares Outstanding (Basic)
61000
Shares Outstanding (Diluted)
61000
Shares Change (YoY)
593.08%157.06%74.04%40.92%146.19%
EPS (Basic)
-2.24-48.96-61.25-120.90-849.15
EPS (Diluted)
-2.24-48.96-61.25-120.90-849.15
Shares Outstanding
7.853.430.360.340.17
Free Cash Flow
-7.05-16.21-20.43-21.27-23.64
Free Cash Flow Per Share
-1.12-17.81-57.70-104.59-163.80
Gross Margin
-83.51%-247.06%--
Operating Margin
--2693.13%-31080.88%--
Profit Margin
--7652.75%-31864.71%--
FCF Margin
--2784.36%-30039.71%--
EBITDA
-9.25-15.54-21.05-33.06-113.62
EBITDA Margin
--2669.24%-30957.35%--
EBIT
-9.32-15.67-21.14-33.22-113.73
EBIT Margin
--2693.13%-31080.88%--
Effective Tax Rate
-0.32%0.07%-0.01%0.18%0.05%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q